Bellevue Group AG Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001674546
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2026 · 153 positions · Total reported value $4.82B · Top-10 concentration 47.1% · Updated 2026-11-17
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
Turnover: 59.4% · 22 new · 62 cut · 17 exited
Active Share (vs S&P 500): 94.3% · vs QQQ: 96.4% — share of the book that differs from index weights (higher = more active) · ranking
In its Q3 2026 13F filing, Bellevue Group AG disclosed 153 equity positions with a combined reported value of $4.82B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 47.1% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2026 were AMGN ($363.21M), GILD ($320.56M), VRTX ($302.46M). By sector, the heaviest allocations are Health Care 97.7%, Industrials 1.6%. Versus the prior quarter, allocation shifted toward Health Care (+5.2pp) and away from Other (-4.8pp).
Versus the prior quarter, Bellevue Group AG opened 22 new positions, trimmed 62 and fully exited 17, a turnover rate of 59.4% of positions. The portfolio's overlap with the prior quarter was 77% of names.
The largest new positions opened in Q3 2026 were KOD ($43.65M), ANRO ($29.71M), LBRX ($27.46M).
Of the 17 positions fully exited versus the prior quarter, the largest were NUVL ($130.08M), CRNX ($98.04M), RARE ($66.20M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2026)
Fully Exited (vs previous quarter)
- NUVL NUVALENT INC · prev qtr: $130.08M
- CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $98.04M
- RARE ULTRAGENYX PHARMACEUTICAL IN · prev qtr: $66.20M
- CLDX CELLDEX THERAPEUTICS INC NEW · prev qtr: $44.65M
- GLUE MONTE ROSA THERAPEUTICS INC · prev qtr: $28.80M
- ANNX ANNEXON INC · prev qtr: $23.41M
- PODD INSULET CORP · prev qtr: $19.41M
- MOH MOLINA HEALTHCARE INC · prev qtr: $6.35M
Insider Transactions (Form 4)
Latest Bellevue Group AG buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Bellevue Group AG files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 153 positions worth $4.82B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).
Portfolio Structure
- 153 positions · $4.82B reported value (Q3 2026)
- Top 10 holdings = 47.1% of reported value
- Largest position: AMGN (AMGEN INC) at 7.5%
- Average position size: $31.50M
Sector Tilt
- Health Care 97.7%
- Industrials 1.6%
- Information Technology 0.5%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q3 2026: 22 new, 42 added, 62 reduced, 17 exited
- 27 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 09:42
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
861.69K | $363.21M | 7.54% | Add | |
| 2 |
|
2.15M | $320.56M | 6.65% | Hold | |
| 3 |
|
578.53K | $302.46M | 6.28% | Hold | |
| 4 |
|
290.51K | $278.57M | 5.78% | Reduce | |
| 5 |
|
279.59K | $212.00M | 4.40% | Add | |
| 6 |
|
998.95K | $205.04M | 4.25% | Reduce | |
| 7 |
|
1.51M | $172.13M | 3.57% | Add | |
| 8 |
|
7.11M | $146.38M | 3.04% | Add | |
| 9 |
|
1.64M | $136.68M | 2.84% | Reduce | |
| 10 |
|
597.92K | $135.06M | 2.80% | Add | |
| 11 |
|
2.79M | $134.66M | 2.79% | Add | |
| 12 |
|
2.32M | $132.14M | 2.74% | Add | |
| 13 |
|
6.19M | $111.66M | 2.32% | Hold | |
| 14 |
|
1.05M | $103.57M | 2.15% | Add | |
| 15 |
|
186.43K | $101.02M | 2.10% | Reduce | |
| 16 |
|
248.00K | $100.85M | 2.09% | Reduce | |
| 17 |
|
1.04M | $90.03M | 1.87% | Add | |
| 18 |
|
1.20M | $78.74M | 1.63% | Add | |
| 19 |
|
2.26M | $68.59M | 1.42% | Reduce | |
| 20 |
|
1.47M | $67.34M | 1.40% | Reduce | |
| 21 |
|
741.88K | $64.02M | 1.33% | Reduce | |
| 22 |
|
4.29M | $60.33M | 1.25% | Add | |
| 23 |
|
490.42K | $59.51M | 1.24% | Add | |
| 24 |
|
240.32K | $59.30M | 1.23% | Add | |
| 25 |
|
185.37K | $51.05M | 1.06% | Reduce | |
| 26 |
|
587.73K | $50.73M | 1.05% | Reduce | |
| 27 |
|
247.73K | $45.68M | 0.95% | Add | |
| 28 |
|
64.75K | $43.71M | 0.91% | Reduce | |
| 29 |
|
460.42K | $43.65M | 0.91% | New | |
| 30 |
|
1.92M | $40.84M | 0.85% | Add | |
| 31 |
|
1.35M | $38.46M | 0.80% | Hold | |
| 32 |
|
206.79K | $37.02M | 0.77% | Add | |
| 33 |
|
560.00K | $36.66M | 0.76% | Hold | |
| 34 |
|
827.68K | $36.13M | 0.75% | Reduce | |
| 35 |
|
2.11M | $35.74M | 0.74% | Add | |
| 36 |
|
97.11K | $35.65M | 0.74% | Reduce | |
| 37 |
|
493.60K | $34.99M | 0.73% | Hold | |
| 38 |
|
379.87K | $33.82M | 0.70% | Add | |
| 39 |
|
61.49K | $32.11M | 0.67% | Hold | |
| 40 |
|
27.48K | $31.80M | 0.66% | Reduce | |
| 41 |
|
143.47K | $31.72M | 0.66% | Reduce | |
| 42 |
|
1.16M | $29.71M | 0.62% | New | |
| 43 |
|
715.51K | $27.46M | 0.57% | New | |
| 44 |
|
1.10M | $27.42M | 0.57% | Add | |
| 45 |
|
76.00K | $25.27M | 0.52% | Reduce | |
| 46 |
|
2.60M | $23.62M | 0.49% | New | |
| 47 |
|
85.83K | $22.72M | 0.47% | Reduce | |
| 48 |
|
347.19K | $22.70M | 0.47% | Add | |
| 49 |
|
1.00M | $22.52M | 0.47% | New | |
| 50 |
|
1.10M | $22.19M | 0.46% | Hold | |
FAQ
What did Bellevue Group AG buy in 2026-Q3?
In its 2026-Q3 13F filing, Bellevue Group AG reported 153 equity positions worth $4.82B in aggregate; its largest disclosed positions were AMGN ($363.21M), GILD ($320.56M), VRTX ($302.46M).
How large is Bellevue Group AG's portfolio?
Bellevue Group AG reported $4.82B of long equity holdings across 153 positions as of 2026-Q3. Top-10 holdings account for 47.1% of reported value.
What is Bellevue Group AG's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.